4:30 PM – 6:30 PM
mRNA – A New Class of Drugs for Musculoskeletal Tissue Regeneration?
This RIG will offer an outstanding discussion on the latest advances in mRNA therapeutics and the challenges that this drug may face when applied to musculoskeletal tissue regeneration among three outstanding speakers. Professor Drew Weissman pioneered the discovery of nucleoside modifications to suppress mRNA immunogenicity. His work has revolutionized the field of mRNA therapeutics, and it was instrumental for the development of the COVID-19 vaccine developed by BioNTech/Pfizer and Moderna. Professor Chris Evans has profound experience in the uses of gene therapy as technology platform to solve clinical problems involving bones and joints. He is the lead investigator in an ongoing clinical trial for the administration of sc-rAAV2.5IL-1Ra, a gene therapy carried by a virus, into the knee joint of patients with osteoarthritis. He has been acknowledged as father of musculoskeletal gene therapy. Professor John Cooke has a deep knowledge in fundamental and translational research, with particular emphasis in vascular regeneration. He has developed numerous therapeutic molecules to address various diseases. He is the founder of a Center for RNA Therapeutics that generates mRNA constructs for stem cell and cancer communities. They have experience in the synthesis, purification, validation, and delivery of RNA Therapeutics, for basic and clinical research.
At the end of this session, attendees will have learned about the advantages of mRNA applied to musculoskeletal repair. In particular, progression in fracture healing will be presented. In addition, remaining challenges of mRNA for this application will be presented and discussed. The attendees will have a unique opportunity to discuss these challenges with the keynote speakers. Possible solutions to tackle present challenges will be presented and discussed. Specifically, application of mRNA for protein expression; advantages of mRNA vs. DNA therapeutics; application of mRNA to musculoskeletal repair: State-of-the art and future perspective; needs and challenges in translating mRNA therapeutics to patient care for musculoskeletal repair